CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Capricor Therapeutics, Inc. following a class action complaint regarding breaches of fiduciary duties by the board of directors during the specified class period [1]. Group 1: Legal Investigation - The law firm is encouraging long-term stockholders of Capricor, specifically those who held shares between October 9, 2024, and July 10, 2025, to discuss their legal rights [1][3]. - A class action complaint was filed against Capricor on July 17, 2025, focusing on the actions of the company's board of directors [1]. Group 2: Company Performance and Issues - The complaint alleges that Capricor misled investors regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [7]. - Capricor's statements included claims about obtaining a Biologics License Application (BLA) from the FDA, while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [7]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [7].